Durect plunges after scrapping psoriasis drug development following trial - InvestingChannel

Durect plunges after scrapping psoriasis drug development following trial

Shares of Durect (DRRX) are under pressure on Thursday after the company announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis, with the drug failing to demonstrate benefit over placebo. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3012214/-Durect-plunges-after-scrapping-psoriasis-drug-development-following-trial)